istock-172687351thedman

TheDman / iStockphoto.com

7 June 2018Americas

Astellas accuses Cipla of infringing overactive bladder patent

Pharmaceutical company Astellas Pharma has filed a patent infringement claim against India-based Cipla over a drug for treating an overactive bladder.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Cipla files defensive patent suit over Ofev generic

8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

More on this story

Cipla files defensive patent suit over Ofev generic

8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

More on this story

Cipla files defensive patent suit over Ofev generic

8 March 2022 Mumbai-based pharma company Cipla has filed a lawsuit asking a Delaware court to rule that its proposed generic of Boehringer Ingelheim’s lung disease treatment Ofev does not infringe two patents.

Astellas-backed Crescendo pairs up with Zai Lab in licensing deal

31 May 2018 UK-based Crescendo Biologics has agreed a global licensing deal with biopharma company Zai Lab which will see Zai Lab develop and commercialise an antibody, “VH domain therapeutic”, for applications in inflammatory diseases.

More features

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant

Mental health IP toolkit: Diversity Champ’s stress-busting tips

Eli Lilly piles on weight loss drug suits to ward off revenue squeeze

Patent cliff: 5 blockbusters running out of road

Herbert Smith Freehills expands German tech patent team

‘Always new twists’: Bayer legal team on defending a $4bn drug

Novartis and MSN feud intensifies after Fed Circ denies rehearing

EU court signals tough stance on ‘pay-for-delay’ pharma deals